[ad_1] TAIPEI and SAN DIEGO, Dec. 10, 2025 /PRNewswire/ — Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company developing first-in-class therapies for difficult-to-treat cancers, today announced a clinical supply agreement with BeOne Medicines, a global […]
[ad_1] TAIPEI and SAN DIEGO, Oct. 20, 2025 /PRNewswire/ — Senhwa Biosciences’s investigational new drug Silmitasertib (CX-4945) was recently featured in an official post by Google DeepMind, following a major breakthrough by the tech giant’s […]
[ad_1] TAIPEI and SAN DIEGO, Nov. 1, 2024 /PRNewswire/ — Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced the appointment of […]
[ad_1] TAIPEI and SAN DIEGO, Sept. 17, 2024 /PRNewswire/ — Senhwa Biosciences, Inc. (TPEx: 6492), , a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that an […]
[ad_1] The study involved end-stage oncology patients with no other suitable treatment options. In this Phase Ib study, Pidnarulex (CX-5461) demonstrated acceptable clinical tolerability and showed preliminary signs of efficacy, even in patients who had […]
